Some takeaways from CC and Financial statement
1/ Cash Flow goes from $C 66,490,000 in Q3 2018 to $C 71,637,000 in Q4 2018. Compare this cash flow to Q4 2017 which was $C 32,929,000. Of course, this increase from 2017 to 2018 was partly due to the convertible debenture, but the increase from Q3 2018 to Q4 2018 was clearly due to operating activities. Looks like Thera wrote off a lot of depreciation/amortization non-cash expenses to come up with a net loss !
2/ Adjusted EBITDA was $C 2,259,000 (or about $C 0.03/share). Of course, nobody wants to report a profit which requires it to pay income tax !
3/ There is an increase of 30% in Trogarzo sales in Jan 2019 as compared to Dec 2018 (per CC)
4/ Around April 2019, revenues of Trogarzo will be equal or surpass Egrifta revenues. And Egrfta sales was $C 46,941,000 as of Q4 2018. So, by extrapolating this number, sales of Trogarzo expects to be at least $C 47 million in 2019.